MB-109

MB-109 is a novel combination therapy developed by Mustang Bio for the treatment of recurrent glioblastoma (GBM) and high-grade astrocytoma. It consists of two agents: MB-101, an IL13Rα2-targeted chimeric antigen receptor (CAR) T-cell therapy, and MB-108, an oncolytic herpes simplex virus type 1 (HSV-1). The regimen is designed to leverage the immunomodulatory effects of the oncolytic virus to reshape the tumor microenvironment—making immunologically "cold" tumors "hot"—and thereby enhance infiltration and efficacy of CAR-T cells targeting IL13Rα2-expressing tumor cells. Preclinical data support this approach as potentially improving outcomes in these aggressive brain cancers. A phase 1 clinical trial is planned to assess safety, tolerability, and efficacy in adults with recurrent GBM or high-grade astrocytomas expressing IL13Rα2[1][2][3][5][7][8].